Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Olaszország2. fázis

Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT MeetURO trial)

A legfontosabb adatok

Ki végzi
Fondazione IRCCS Istituto Nazionale Dei Tumori
Hol
Milan (Olaszország)A helyszín megnézése
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
23 fő, tervezett
Kezdés
2024. dec. 23.
Várható befejezés
2029. dec. 23.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. szeptember 23.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek előrehaladott vagy áttétes gyűjtőcsatorna-karcinómájuk vagy vese-velőállományi karcinómájuk van, ami ritka vesedaganat. A pembrolizumab és az enfortumab vedotin együttes hatását vizsgálják.

Életkor
18 éves vagy idősebb
Nem
Nők és férfiak egyaránt részt vehetnek.
A betegség stádiuma
Áttétes vagy előrehaladott gyűjtőcsatorna-karcinóma vagy vese-velőállományi karcinóma, szövettanilag igazolva és központi patológiai vizsgálattal megerősítve. A betegségnek mérhetőnek kell lennie a képalkotó vizsgálatokon (RECIST 1.1).
Korábbi kezelés
Korábban nem kaphatott anti-PD-1, anti-PD-L1 vagy anti-PD-L2 gyógyszert. A kezelés kezdete előtti 2 héten belül nem kaphatott más daganatellenes gyógyszeres kezelést.

A részvétel fő kizáró okai

  • Korábbi anti-PD-1, anti-PD-L1 vagy anti-PD-L2 kezelés
  • Aktív agyi áttét vagy carcinomás agyhártyagyulladás
  • Aktív autoimmun betegség, amely az elmúlt 2 évben kezelést igényelt
  • Korábbi vagy jelenlegi tüdőgyulladás vagy intersticiális tüdőbetegség, amely szteroidot igényelt
  • Terhes vagy szoptató nők, illetve másik személytől származó szerv- vagy szövetátültetés

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic or advanced Collecting Duct Carcinoma or Medullary Renal Cell Carcinoma will be enrolled in this study
  • Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to treatment allocation. Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. Hepatitis B screening tests are not required unless: • Known history of HBV infection • As mandated by local health authority
  • Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to treatment allocation. Hepatitis C screening tests are not required unless: • Known history of HCV infection • As mandated by local health authority
  • HIV-infected participants must have well-controlled HIV on ART. Please refer to the study protocol for the full text
  • The participant provides written informed consent for the trial
  • Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • Have confirmed histology diagnosis of Collecting Duct Carcinoma or Medullary Renal Cell Carcinoma by central pathology review
  • Archival tumor tissue sample or newly obtained [core, incisional or excisional] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention
  • Have adequate organ function as defined in the following table (Table 4). Specimens must be collected within 10 days prior to the start of study intervention

Ki nem vehet részt

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
  • Has received prior systemic anti-cancer therapy, including investigational agents, within 2 weeks prior to treatment allocation
  • Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS diseases permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention
  • Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
  • Known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA <10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention
  • Has not adequately recovered from major surgery or has ongoing surgical complications
  • Has had an allogenic tissue/solid organ transplant
  • Has a history of hypersensitivity reaction to Enfortumab Vedotin active substance and/or to any of the excipients
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
  • Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Incapacitated participants - as not all requirements set in Article 31 of Reg EU 536/2014 are met, especially letter (e)
  • Females who are pregnant, breastfeeding, or planning to conceive a child during the study duration (from screening through 12 months after the last dose of trial treatment) are excluded. Additionally, male participants who plan to father a child during treatment or within 9 months after the last dose of trial treatment are also excluded

Helyszínek itt: Olaszország

  • Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, OlaszországToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate activity of the combination Enfortumab Vedotin plus Pembrolizumab in terms of ORR.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
A regiszteradat frissítve
2026. szeptember 23.